GlassScriptPhysician profile
Lea M Bannister
NPI 1922034271
$3,178.98
in general payments reported to CMS, 2019-2025
35 companies · $445 in 2025
The $445 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $175 · 2021: $754 · 2022: $414 · 2023: $652 · 2024: $491 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $344.84 | 2019-2025 | Injectafer |
| Abbvie INC. | $311.00 | 2019-2024 | Orilissa, Lo Loestrin Fe, Ubrelvy |
| Exeltis, USA INC. | $241.76 | 2019-2025 | Slynd |
| Pfizer INC. | $237.84 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $223.34 | 2021-2025 | |
| Shield Therapeutics INC | $166.22 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $162.18 | 2021-2025 | Veozah |
| Hologic Sales and Service, LLC | $160.00 | 2021-2025 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Novo Nordisk INC | $156.65 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.43 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $102.28 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $90.77 | 2019-2022 | |
| Biogen, INC. | $76.40 | 2024-2025 | Zurzuvae |
| Organon LLC | $66.43 | 2024-2025 | Jada System |
| Duchesnay USA Incorporated | $65.83 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $63.73 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $61.50 | 2019-2021 | |
| Coopersurgical, INC. | $55.06 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $52.90 | 2019-2021 | |
| Agile Therapeutics, INC. | $51.66 | 2021-2022 | |
| Myovant Sciences INC. | $42.20 | 2022 | |
| Glaxosmithkline, LLC. | $41.95 | 2021 | |
| Mylan Pharmaceuticals INC. | $40.42 | 2020-2022 | |
| Scynexis, INC. | $33.10 | 2022 | |
| Seqirus USA INC | $29.92 | 2025 | Flucelvax |
| Evofem Biosciences, INC. | $25.23 | 2021 | |
| Gynesonics, INC. | $19.77 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Takeda Pharmaceuticals U.S.A., INC. | $19.68 | 2021 | |
| Urovant Sciences INC | $16.39 | 2022 | |
| Minerva Surgical, INC | $15.00 | 2021 | |
| Medtronic, INC. | $14.03 | 2023 | Truclear |
| Lilly USA, LLC | $13.33 | 2024 | Zepbound |
| Boston Scientific Corporation | $12.74 | 2019 | |
| Amgen INC. | $11.99 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Bannister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.